F. Gómez

Phase III Randomized Trial of <i>Calendula Officinalis</i> Compared With Trolamine for the Prevention of Acute Dermatitis During Irradiation for Breast Cancer

P. Pommier, F. Gómez, Marie Pierre Sunyach et al. · Journal of Clinical Oncology · 2004 · 364 citations · Full text

Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial.

Cesare Guglielmi, F. Gómez, Thierry Philip et al. · Journal of Clinical Oncology · 1998 · 156 citations

Impact of targeting deviations on outcome in medulloblastoma: study of the French society of pediatric oncology (SFOP)11Participating institutions including more than one patient: Centre Paul Papin—Angers (M. Mege); Bruxelles (C. De Vriendt); Centre Claudius Regaud—Toulouse (F. Soum); Hôpital Charles Nicolle—Rouen (S. Seng); Institut Jean Godinot—Reims (X. Panis); Hôpital Bellevue—Saint-Etienne (T. Schmitt).

C. Carrié, S. Hoffstetter, F. Gómez et al. · International Journal of Radiation Oncology*Biology*Physics · 1999 · 154 citations

Neuro-oncology, Pediatric Brain Tumors, Pediatric Neurosurgery +11

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19

Simin Florescu, Delia Stanciu, Mihaela Zaharia et al. · JAMA · 2022 · 147 citations · Full text

Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial

Simin Florescu, Delia Stanciu, Mihaela Zaharia et al. · JAMA · 2022 · 133 citations · Full text